1. Han M, Toli J, Abdellatif M. MicroRNAs in the cardiovascular system. Curr Opin Cardiol. 2011; 26:181–189.
Article
2. Ma S, Ma CC. Recent development in pleiotropic effects of statins on cardiovascular disease through regulation of transforming growth factor-beta superfamily. Cytokine Growth Factor Rev. 2011; 22:167–175.
Article
3. Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature. 2011; 469:336–342.
Article
4. Chiong M, Cartes-Saavedra B, Norambuena-Soto I, Mondaca-Ruff D, Morales PE, García-Miguel M, et al. Mitochondrial metabolism and the control of vascular smooth muscle cell proliferation. Front Cell Dev Biol. 2014; 2:72.
Article
5. Chistiakov DA, Orekhov AN, Bobryshev YV. Vascular smooth muscle cell in atherosclerosis. Acta Physiol (Oxf). 2015; 214:33–50.
Article
6. Psaltis PJ, Simari RD. Vascular wall progenitor cells in health and disease. Circ Res. 2015; 116:1392–1412.
Article
7. Millette E, Rauch BH, Kenagy RD, Daum G, Clowes AW. Platelet-derived growth factor-BB transactivates the fibroblast growth factor receptor to induce proliferation in human smooth muscle cells. Trends Cardiovasc Med. 2006; 16:25–28.
Article
8. Raines EW. PDGF and cardiovascular disease. Cytokine Growth Factor Rev. 2004; 15:237–254.
Article
9. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008; 22:1276–1312.
Article
10. Getachew R, Ballinger ML, Burch ML, Reid JJ, Khachigian LM, Wight TN, et al. PDGF beta-receptor kinase activity and ERK1/2 mediate glycosaminoglycan elongation on biglycan and increases binding to LDL. Endocrinology. 2010; 151:4356–4367.
Article
11. Nouraee N, Mowla SJ. miRNA therapeutics in cardiovascular diseases: promises and problems. Front Genet. 2015; 6:232.
Article
12. Alvarez-Garcia I, Miska EA. MicroRNA functions in animal development and human disease. Development. 2005; 132:4653–4662.
Article
13. Costa FF. Non-coding RNAs: new players in eukaryotic biology. Gene. 2005; 357:83–94.
Article
14. Mendell JT. MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle. 2005; 4:1179–1184.
Article
15. He Y, Lin J, Kong D, Huang M, Xu C, Kim TK, et al. Current state of circulating MicroRNAs as cancer biomarkers. Clin Chem. 2015; 61:1138–1155.
Article
16. Ohtsuka M, Ling H, Doki Y, Mori M, Calin GA. MicroRNA processing and human cancer. J Clin Med. 2015; 4:1651–1667.
Article
17. Tuna M, Machado AS, Calin GA. Genetic and epigenetic alterations of microRNAs and implications for human cancers and other diseases. Genes Chromosomes Cancer. 2016; 55:193–214.
Article
18. Xu Z, Han Y, Liu J, Jiang F, Hu H, Wang Y, et al. MiR-135b-5p and MiR-499a-3p promote cell proliferation and migration in atherosclerosis by directly targeting MEF2C. Sci Rep. 2015; 5:12276.
Article
19. Liu K, Ying Z, Qi X, Shi Y, Tang Q. MicroRNA-1 regulates the proliferation of vascular smooth muscle cells by targeting insulin-like growth factor 1. Int J Mol Med. 2015; 36:817–824.
Article
20. Xie B, Zhang C, Kang K, Jiang S. miR-599 inhibits vascular smooth muscle cells proliferation and migration by targeting TGFB2. PLoS One. 2015; 10:e0141512.
Article
21. Khan S, Brougham CL, Ryan J, Sahrudin A, O'Neill G, Wall D, et al. miR-379 regulates cyclin B1 expression and is decreased in breast cancer. PLoS One. 2013; 8:e68753.
Article
22. Rigalli JP, Ciriaci N, Arias A, Ceballos MP, Villanueva SS, Luquita MG, et al. Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity. PLoS One. 2015; 10:e0119502.
Article
23. Yamamoto K, Seike M, Takeuchi S, Soeno C, Miyanaga A, Noro R, et al. MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma. Oncol Rep. 2014; 32:2365–2372.
Article
24. Bayes-Genis A, Conover CA, Schwartz RS. The insulin-like growth factor axis: a review of atherosclerosis and restenosis. Circ Res. 2000; 86:125–130.
25. Zhu B, Zhao G, Witte DP, Hui DY, Fagin JA. Targeted overexpression of IGF-I in smooth muscle cells of transgenic mice enhances neointimal formation through increased proliferation and cell migration after intraarterial injury. Endocrinology. 2001; 142:3598–3606.
Article
26. Delafontaine P. Insulin-like growth factor I and its binding proteins in the cardiovascular system. Cardiovasc Res. 1995; 30:825–834.
Article